Business
Quest PharmaTech Announces Formation of Clinical Advisory Panel
Quest PharmaTech Announces Formation of Clinical Advisory Panel
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\n Jul. 9, 2010 (Canada NewsWire Group) -- TSX Venture: QPT\n\n Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the formation of an international clinical advisory panel (the "Panel").\nThis Panel of international experts with special expertise in ovarian cancer has been charted to guide the Company through the conduct and analysis of its clinical trials program with Oregovomab as well as to provide strategic guidance on other programs.\n"The formation of the Clinical Advisory Panel is indicative of our progression as a cancer immunotherapy company and we look forward to working with these Panel members to advance our clinical programs", said Dr. Madi R. Madiyalakan, Quest's Chief Executive Officer. The Company plans to initiate three clinical studies with Oregovomab, one in combination with front line therapy, one in combination with gemcitabine in CA125 expressing pancreatic cancer, and one in combination with the TLR3 agonist, rintatolimod.\nThe Panel will be chaired by Christopher Nicodemus, MD, FACP, a clinical expert in tumor immunology and drug development, formerly of Brigham and Women's Hospital, Harvard Medical School, who is very familiar with the Oregovomab clinical program. He currently is Chairman and Chief Scientific Officer of Advanced Immune Therapeutics Inc, of Charlestown, Massachusetts, a private biotechnology company exploring the role of IgE as a cancer therapeutic and also the potential of various adjuvant strategies for immunotherapy.\nJoining Dr. Nicodemus in the U.S. is Professor William McGuire, formerly of Johns Hopkins University and currently Medical Director of the Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center in Baltimore, Maryland. Dr. McGuire is a leading clinical oncologist with a special interest in ovarian cancer and pioneer to improving outcomes in this disease. Dr. McGuire was instrumental in developing the paclitaxel plus cisplatin combination - the foundation for the standard treatment of advanced ovarian cancer.\nFrom Europe, the Panel will include Professor Ignace Vergote, head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven....